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Summary In persons with Down’s syndrome (DS) immunological ab-
normalities as well as hypothyroidism and Alzheimer type dementia are
frequently observed. In addition, the activity of the enzyme cystathionine
beta-synthase (CBS) is over-expressed which results in an altered homo-
cysteine metabolism.
In the present study, 48 older healthy DS persons without signs of
dementia, psychiatric or somatic comorbidity and free of medication were
analyzed for plasma levels of amino acids, neopterin and monoaminergic
metabolites. Data were compared with those obtained from age and sex
matched healthy controls.
It was found that the spectrum of amino acids showed widespread differ-
ences in that levels of nearly all essential amino acids were lower in DS
patients as compared to healthy controls. In addition, a signiﬁcantly lower
methionine and higher taurine concentration were observed which is in
accordance with a disturbed homocysteine metabolism. With respect to
the monoamine metabolites, the concentration of 5-hydroxyindoleacetic acid
was not altered whereas that of homovanillic acid was signiﬁcantly
increased. Finally, the concentration of the immune activation marker neop-
terin was increased in persons with DS.
It is concluded that healthy DS persons of older age show extensive
biochemical abnormalities suggesting a compromised homocysteine me-
tabolism, an activated cell-mediated immune response and an enhanced
turnover of dopamine.
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Introduction
Down’s syndrome (DS) or trisomy 21 is the most common
form of intellectual disability with an overall prevalence
of 1.42=1000 that increases signiﬁcantly with maternal
age (Bray et al., 1998). Immunological abnormalities like
functional impairments in fagocytes with low chemotactic
ability as well as the depressed production of cytokines
are intrinsic to the chromosomal disorder and result in an
increased morbidity and mortality from infectious dis-
eases (Ugazio et al., 1990). In addition, DS is associated
with hypothyroidism in 20–40% of the patients and
with neuropsychiatric disorders of which depression and
Alzheimer-type dementia are the most frequent (Lovell
and Reiss, 1993; Prasher, 1999; Bush and Beail, 2004).
Since the activity of the enzyme cystathionine b-synthase
(CBS), which is encoded on chromosome 21 (21q22.3), is
associated with the level of intelligence and with neuro-
psychiatric disorders (Abbott et al., 1987; Barbaux et al.,
2000), the concentration of CBS was recently investigated
in postmortem brains of DS persons (Ichinohe et al., 2005).
It was found that the concentration of CBS was three times
higher as compared to brain levels of normal individuals.
CBS catalyzes the conversion of homocysteine and serine
into cystathionine. The latter dipeptide is further metabo-
lized into the amino acids cysteine and eventually to tau-
rine. In humans, the sole source of homocysteine is through
dietary intake of the essential amino acid methionine
(Selhub et al., 1999; Ward et al., 2000).
Thus, the over-expression of CBS in persons with DS
may alter homocysteine metabolism resulting in a meta-
bolic imbalance such that folate-dependent resynthesis of
methionine is compromised, and may be in favour of the
transsulfuration pathway, leading eventually to increased
Correspondence: Prof. Dr. W. M. A. Verhoeven, Vincent van Gogh Institute
for Psychiatry, Stationsweg 46, 5803 AC Venray, The Netherlands
e-mail: wverhoeven@vvgi.nllevels of taurine (Huxtable, 1992). Due to the dosage effect
of CBS, a decrease in plasma concentration of serine was
found in DS persons. In addition, an increase in plasma
lysine, which was explained by generalized premature
aging in DS, was observed (Mircher et al., 1997).
Another amino acid abnormality is a decrease of sys-
temic glutamate uptake as assessed by measuring gluta-
mate uptake in platelets and ﬁbroblasts from DS persons
(Begni et al., 2003). The authors suggest the use of this
peripheral model as a biochemical ex vivo marker of a
central glutamatergic dysfunction. Excessive glutamatergic
stimulation as a consequence of glutamate uptake deﬁcits
could be responsible for neuronal suffering, excitoxicity
and cell death, and may play a key role in the patho-
physiology of neuropsychiatric disorders (review: Van der
Heijden et al., 2004).
Apart from the abovementioned amino acid abnormal-
ities, impaired immunological function in DS persons
results in increased serum neopterin levels (Mehta et al.,
2005). Neopterin is not only an immune activator for the
cell-mediated immune response, but also induces or
enhances cytotoxicity and exhibits antioxidant properties
(Hamerlinck, 1999). This observation is consistent with
the increased susceptibility of DS persons to bacterial and
viral infections (Cossarizza et al., 1990).
No studies have been reported on the measurement of
peripheral precursors or metabolites of the neurotransmit-
ters serotonin and dopamine in DS. Since serotonin is
involved in brain growth and maturation, and experimen-
tally induced high dopamine turnover may give rise to toxic
metabolites and neurodegeneration (Ogawa et al., 1993;
Alexander et al., 1997; Kupsch et al., 2001), measurement
of peripheral correlates of central serotonin and dopamine
metabolism is also warranted. Since at least 40% of circu-
lating homovanillic acid (HVA) originates form the brain,
the plasma HVA concentration is thought to be a fairly
good indicator of the changes in dopamine metabolism
in the brain (Kendler et al., 1982). In addition, plasma
5-hydroxyindoleacetic acid (5-HIAA) is suggested to be
an indicator of brain serotonergic activity (Meltzer, 1989).
The present study was designed to investigate peripheral
parameters that reﬂect changes in homocysteine metabo-
lism, immune function and monoaminergic neurotransmis-
sion in a group older non-demented healthy persons with
DS. To this end, especially the sulphur containing amino
acids methionine and taurine as well as serine, glycine,
glutamate, lysine, tryptophan and the other large neutral
amino acids (LNAA) were measured. The ratio of tryp-
tophan to LNAA is a fairly good indicator of central
serotonin synthesis. Concentrations of the dopamine and
serotonin metabolites HVA and 5-HIAA were determined
as well as the levels of the immune activation marker
neopterin.
Materials and methods
Subjects
Over a period of 4 years a community based sample of 505 DS persons
aged 45 year and older from the Southern and the South-Western parts of
the Netherlands was collected. The study protocol was approved by the
Medical Ethetical Committee of the Erasmus University Medical Centre
in Rotterdam, The Netherlands (protocol number: MEC 185.974=
1999=202). In addition, the ethical committee of the local institutions
provided approval. Written informed consent was obtained from the
legal representatives. Details of the study population and the used
screening instruments are presented elsewhere (Coppus et al., 2006).
For the present study persons were excluded in case of any relevant
somatic comorbidity, including hypothyroidism and epilepsy, or the pres-
ence of a depressive disorder and signs of dementia. All persons were free
of medication, including the use of folic acid, and did not smoke. The study
group comprised 48 persons with DS (female: 11; male: 37; mean age:
50   4.8 years) of whom 2 had to be excluded because of laboratory
problems, and was compared to a group of 48 age and sex matched healthy
controls (female: 16; male: 32; mean age: 50.2   9.1 years).
Biochemical analyses
Plasma amino acids are analyzed by high-performance liquid chromatog-
raphy (HPLC) using pre-column derivatization with o-phthaldialdehyde
(Fekkes et al., 1995). The tryptophan-ratio (Trp-ratio) is calculated by
dividing the total tryptophan level by the sum of the other large neutral
amino acids (LNAA), i.e. valine, isoleucine, leucine, tyrosine and phenyl-
alanine, which compete for the transport of tryptophan through the blood–
brain barrier. The tyrosine-ratio (Tyr-ratio) is calculated in the same manner
by substituting tryptophan for tyrosine. The concentrations of the mono-
amine metabolites 5-HIAA and HVA are analyzed by HPLC and electro-
chemical detection (Fekkes et al., 1997). The concentration of neopterin in
plasma is determined as previously described (Hoekstra et al., 2001).
Statistical analyses
For statistical comparisons between persons with DS and controls, the
unpaired t-test was used because all data sets showed a normal distribution.
Normality of the distribution was tested with the Kolmogorov-Smirnov test.
A value of p<0.05 was considered to be statistically signiﬁcant. In case of
ﬁnding statistically signiﬁcant values for biochemical parameters, discrimi-
nant analysis was performed in order to assess the potential for further
differentiating DS persons from controls, and to establish their relative
contribution to the group difference.
Results
As can be inferred from Table 1, the concentrations of
methionine, glutamate and all LNAA are signiﬁcantly de-
creased in the DS group as compared to the control group.
Of the LNAA, tryptophan shows the lowest signiﬁcance.
The concentrations of taurine and glycine are signiﬁcantly
increased in DS persons as compared to controls, whereas
the level of glutamate is signiﬁcantly decreased. In addi-
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higher in the DS group compared to the controls.
With respect to neopterin, values in the DS group are
signiﬁcantly increased as compared to the control group.
Furthermore, plasma HVA concentrations are signiﬁcantly
higher in the DS group, whereas no differences are found
regarding 5-HIAA concentrations.
Finally, discriminant analysis (stepwise method) of the
biochemical parameters with p-values <0.001 (valine, iso-
leucine, leucine, methionine, taurine and Trp-ratio) results in
a discriminant function with valine, methionine and taurine
as major predictors. Classiﬁcation results are good: 84.8%
of the DS persons were correctly classiﬁed as were 83.3%
of the controls. As a whole 16% was wrongly classiﬁed.
Discussion
In the present study biochemical parameters related to
neurotransmission and immunological function were in-
vestigated in a group of older persons with Down’s syn-
drome. It was found that the spectrum of amino acids
shows widespread differences in the DS group as com-
pared to controls. More speciﬁc, the amino acids valine,
methionine and taurine were demonstrated to differentiate
persons with DS from controls. Nearly all values of amino
acids are lower in the DS group, which cannot be ex-
plained from dietary effects since all persons were pro-
vided with well balanced meals. Besides, Ciaccio et al.
(2003) reported that dietary measures over one year have
an only marginal inﬂuence on the plasma concentration
of amino acids in children with DS.
With respect to the CBS-related parameters, plasma
methionine was found to be signiﬁcantly lower, while tau-
rine was higher. In addition, plasma serine was slightly
decreased in DS persons. These observations are in accor-
dance with an over-expression of the CBS-gene in DS
(Chadefaux et al., 1985; Progribna et al., 2001; review:
Chango et al., 2002) and are also in line with results con-
cerning serine and taurine plasma concentrations as re-
ported by Mircher et al. (1997). Although homocysteine
was unfortunately not measured in this primarily epidemi-
ological study, these data corroborate an altered homocys-
teine metabolism in persons with DS and are as such in line
with the lowered plasma concentration of homocysteine
reported by Pogribna et al. (2001). Other investigators,
however, reported increased concentrations of homocysteine
(Brattstrom et al., 1989; Gu e eant et al., 2005). As reviewed
by Townsend et al. (2004), the sulphur containing amino
acids methionine, homocysteine and taurine are involved in
the maintenance and integrity of cellular systems by inﬂu-
encing cellular redox state and cellular capacity to detoxify
toxic compounds, free radicals and reactive oxygen spe-
cies. An imbalance of these amino acids in DS persons
may indicate neuropathological changes in this group.
The increased Trp-ratio in the DS group suggests an
enhanced availability of tryptophan for the synthesis of
serotonin in the central nervous system. Whether central
serotonergic neurotransmission is increased in DS persons
cannot be concluded from this study, especially since the
plasma concentration of 5-HIAA is not changed. The latter
parameter, however, is only a very weak and indirect mea-
sure of central serotonergic activity (Lambert et al., 1995).
Table 1. Plasma levels (mean   SD) of biochemical parameters in DS persons and controls
Biochemical parameter DS patients (n) Healthy controls (n) Signiﬁcance
Tryptophan (mmol=l) 47.1   6.1 (46) 50.4   9.0 (48) p¼0.040
Tyrosine (mmol=l) 61.9   12.6 (46) 71.0   17.3 (48) p¼0.004
Valine (mmol=l) 226.5   42.8 (46) 286.2   59.7 (48) p<0.000
Phenylalanine (mmol=l) 58.0   8.5 (46) 63.1   10.0 (48) p¼0.010
Isoleucine (mmol=l) 61.2   11.7 (46) 82.7   24.1 (48) p<0.000
Leucine (mmol=l) 122.6   20.9 (46) 148.5   31.8 (48) p<0.000
Methionine (mmol=l) 25.6   4.7 (46) 32.0   6.5 (48) p<0.000
Taurine (mmol=l) 53.9   11.8 (46) 42.9   7.6 (48) p<0.000
Serine (mmol=l) 103.7   17.3 (46) 109.8   19.1 (48) p¼0.106
Lysine (mmol=l) 199.3   31.8 (46) 186.3   35.7 (48) p¼0.065
Glycine (mmol=l) 244.6   48.7 (46) 213.0   43.5 (48) p¼0.001
Glutamate (mmol=l) 37.4   22.5 (46) 47.7   20.3 (48) p¼0.021
Trp-ratio 9.0   1.5 (46) 7.9   1.5 (48) p<0.000
Tyr-ratio 12.2   3.3 (46) 11.3   2.1 (48) p¼0.113
Neopterin (nmol=l) 20.4   5.8 (43) 17.4   3.7 (28) p¼0.008
HVA (nmol=l)
a 64.1   16.5 (45) 53.2   12.9 (41) p¼0.001
5-HIAA (nmol=l)
b 43.5   9.0 (45) 41.5   12.9 (42) p¼0.405
a HVA Homovanillic acid.
b 5-HIAA 5-Hydroxyindoleacetic acid.
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cantly increased, which is an indication of a higher turn-
over of dopamine that was reported previously also in
cerebrospinal ﬂuid studies in persons with DS (Kay et al.,
1987; Schapiro et al., 1987).
Neopterin is increased in the DS group as compared to
controls. This ﬁnding is in agreement with the observa-
tions by Metha et al. (2005) who additionally reported that
increase of neopterin is not correlated with age and sex.
High concentrations of neopterin as seen in DS is con-
sistent with the impaired immune function that was re-
ported in persons with DS (Nespoli et al., 1993; Park et al.,
2000).
In conclusion, in the present study of persons with DS
without any signs of dementia, somatic and=or neuro-
psychiatric comorbidity and free of any medication, exten-
sive biochemical abnormalities are found suggesting a
compromised homocysteine metabolism, an activated cell-
mediated immune response and an enhanced turnover of
dopamine. Interestingly, a few peripheral biochemical pa-
rameters appeared to have a marked potential to differenti-
ate between DS persons from controls.
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